title: Heterogeneous response to the growth factors [EGF, PDGF (bb), TGF-alpha, bFGF, IL-2] on glioma spheroid growth, migration and invasion.
abstract: The effects of 5 different growth factors [EGF, PDGF(bb), TGF-alpha, bFGF and IL-2] were studied on tumour spheroids obtained from 5 different human glioma cell lines (U-251MG, D-263MG, D-37MG, D-54MG, GaMG). The expression of EGF and PDGF receptors as well as the endogenous production of TGF-alpha and PDGF were studied by Northern blot analyses. After growth-factor-exposure, tumour spheroid volume growth, and directional cell migration from the spheroids were studied. In addition, tumour-cell invasion was studied in vitro, where foetal rat-brain aggregates were used as a target for the tumour cells. In all the assays a common stimulator for most of the cell lines was EGF. The other growth factors had a more heterogeneous stimulatory effect. Tumour-cell invasion, cell growth and cell migration are biological properties which are not necessarily related to each other. This may explain why the tumours often responded differently to the growth factors in the various assay systems. Two of the cell lines studied were non-invasive (U-251MG, D-263MG). It is shown that these were stimulated both in the directional migration assay and in the spheroid-volume-growth assay. However, their non-invasive behaviour was not influenced by the growth factors studied.
authors.affiliation: Gade Institute, Department of Pathology, Haukeland Hospital, University of Bergen, Norway.
authors.forename: P H
authors.initials: PH
authors.lastname: Pedersen
authors.forename: G O
authors.initials: GO
authors.lastname: Ness
authors.forename: O
authors.initials: O
authors.lastname: Engebraaten
authors.forename: R
authors.initials: R
authors.lastname: Bjerkvig
authors.forename: J R
authors.initials: JR
authors.lastname: Lillehaug
authors.forename: O D
authors.initials: OD
authors.lastname: Laerum
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D001921:Brain / Q000166:cytology; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology; D002449:Cell Aggregation / Q000502:physiology; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology*; D006133:Growth Substances / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D009361:Neoplasm Invasiveness; D010641:Phenotype; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017978:Receptors, Growth Factor / Q000502:physiology; D016211:Transforming Growth Factor alpha / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D006133:Growth Substances; D007376:Interleukin-2; D010982:Platelet-Derived Growth Factor; D012333:RNA, Messenger; D017978:Receptors, Growth Factor; D016211:Transforming Growth Factor alpha; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor